Literature DB >> 23722300

S100P predicts prognosis and drug resistance in gastric cancer.

Fulin Ge1, Changzheng Wang, Weihua Wang, Benyan Wu.   

Abstract

PURPOSE: S100P has been shown to participate in processes of various human malignancies. In this study, we analyzed the tissue expression of S100P in gastric cancer and evaluated its significance.
METHODS: We determined the S100P expression in 156 gastric cancer patients by quantitative RT-PCR. Tumor characteristics and overall survival (OS) for each patient were examined. In vitro experiments were conducted to examine whether ectopic expression of S100P modifies the proliferation and drug resistance of gastric cancer cells.
RESULTS: Higher expression of S100P occurred in human gastric cancer tissues in comparison with normal controls. Highly expressed S100P in gastric cancer was correlated with TNM stage and prognosis. The 5-year survival rate was significantly lower in patients with high levels of S100P expression than in patients with low levels of expression. Ectopic expression of S100P was associated with an increase in tumor cell proliferation and drug resistance.
CONCLUSION: The expression of S100P in human gastric cancer tissues was upregulated in comparison with normal controls. By establishing an association between S100P expression and shortened OS, increase in proliferation and drug resistance, this study indicates that S100P may be a useful prognostic marker for gastric cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23722300     DOI: 10.5301/jbm.5000034

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  11 in total

1.  High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancer.

Authors:  Xiangyu Wang; Tian Tian; Xukun Li; Meng Zhao; Yanhui Lou; Jingfeng Qian; Zhihua Liu; Hongyan Chen; Zhumei Cui
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro.

Authors:  Lei Dong; Fule Wang; Xiaona Yin; Ling Chen; Gang Li; Feiyan Lin; Wuhua Ni; Jianbo Wu; Rong Jin; Lei Jiang
Journal:  Mol Cell Biochem       Date:  2014-01-01       Impact factor: 3.396

Review 3.  What gastric cancer proteomic studies show about gastric carcinogenesis?

Authors:  Mariana Ferreira Leal; Fernanda Wisnieski; Carolina de Oliveira Gigek; Leonardo Caires do Santos; Danielle Queiroz Calcagno; Rommel Rodriguez Burbano; Marilia Cardoso Smith
Journal:  Tumour Biol       Date:  2016-04-28

Review 4.  The life and works of S100P - from conception to cancer.

Authors:  Filip Prica; Tomasz Radon; Yuzhu Cheng; Tatjana Crnogorac-Jurcevic
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

5.  A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours.

Authors:  Juan Martínez-Aguilar; Roderick Clifton-Bligh; Mark P Molloy
Journal:  BMC Cancer       Date:  2015-03-29       Impact factor: 4.430

6.  Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance.

Authors:  Adriana Gibadulinova; Michal Pastorek; Pavel Filipcik; Peter Radvak; Lucia Csaderova; Borivoj Vojtesek; Silvia Pastorekova
Journal:  Oncotarget       Date:  2016-04-19

7.  S100P is a molecular determinant of E-cadherin function in gastric cancer.

Authors:  Patrícia Carneiro; Ana Margarida Moreira; Joana Figueiredo; Rita Barros; Patrícia Oliveira; Maria Sofia Fernandes; Anabela Ferro; Raquel Almeida; Carla Oliveira; Fátima Carneiro; Fernando Schmitt; Joana Paredes; Sérgia Velho; Raquel Seruca
Journal:  Cell Commun Signal       Date:  2019-11-25       Impact factor: 5.712

8.  Prognostic Value of S100P Expression in Patients With Digestive System Cancers: A Meta-Analysis.

Authors:  Bi-Xia Liu; Chao-Tao Tang; Xi-Jian Dai; Ling Zeng; Fei Cheng; Youxiang Chen; Chunyan Zeng
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

9.  Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen.

Authors:  Joe Abdo; Christopher S Wichman; Nicholas E Dietz; Pawel Ciborowski; John Fleegel; Sumeet K Mittal; Devendra K Agrawal
Journal:  Front Oncol       Date:  2018-05-09       Impact factor: 6.244

10.  Loss-of-function tolerance of enhancers in the human genome.

Authors:  Duo Xu; Omer Gokcumen; Ekta Khurana
Journal:  PLoS Genet       Date:  2020-04-03       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.